REYKJAVIK, ICELAND - 16 August 2023 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutic addressing chronic airway diseases, will have data presented in three abstracts at the European Respiratory Society (ERS) International Congress 2023 in Milan, Italy.

EpiEndo Pharmaceuticals announces that CEO, Maria Bech, and CFO, Stefán Pétursson, will be attending the BIO International Convention from June 5-8 at the Boston Convention & Exhibition Center in Boston, Massachusetts.

EpiEndo Pharmaceuticals has appointed Dr Kate Hanrott as Director of Clinical Operations and Sciences, with immediate effect.

SCIENCE4PEACE is a unique manifestation of the Swedish - American Life Science Summit (SALSS) together with The Galien Foundation, taking place in Stockholm, Sweden on the 12th of December during the Nobel festivities.

EpiEndo Pharmaceuticals has received regulatory approval to commence a Phase 2a clinical trial with lead molecule EP395 in COPD (Chronic Obstructive Pulmonary Disease) patients.

EpiEndo Pharmaceuticals has received regulatory and ethics approval to commence a Lipopolysaccharide (LPS) challenge clinical trial with lead molecule EP395.

EpiEndo Pharmaceuticals has completed its Phase I First Time in Human (FTIH) study with EP395 in healthy subjects.

EpiEndo Pharmaceuticals has appointed two new non-executive board members following the departure of Robert Helgason, who stepped down at the Company’s AGM on 26 April 2022.

EpiEndo Pharmaceuticals has expanded its operations with a new laboratory facility in Sweden and new staff hired to key positions.